Ionis Pharmaceuticals, Inc. Common Stock(IONS)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $40.03 – $86.74
- YTD
- -33.14%
- IV Rank (30D)
- 64.26
- Straddle Price
- $4.83
- P/C Vol Ratio
- 10.96
- Market Cap
- $8.9B
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.65% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 9.40% (VRP-adj) |
| WACC | 8.84% |
| Volatility Risk Premium | -4.8pp (IV − HV30), ERP adj -25bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 5 years explicit + fade |
| Free Cash Flow (TTM) | $-1.0B |
| Return on Equity (TTM) | -66.5% |
| Book / Price | 5.5% |
| Gross Margin (TTM) | 98.4% |
| FCF Margin (TTM) | -91.8% |
| Debt / Equity | 2.69 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $70.27 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $62.54 |
| Bollinger Width / SMA20 | 123.5% (drives anchor stability) |
| Net Debt | $1.1B |
| Market Cap | $9B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 33.5× · 8 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.5× · 8 peers |
| Peer P/B | $20.92 | 16% | median 7.1× · 7 peers |
| Peer P/S | $44.30 | 16% | median 7.0× · 8 peers |
| Market Anchor (SMA50) | $70.27 | 68% | stability 83% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $8.9B
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ioni…
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -2.05% | 11 |
| Feb | -1.70% | 11 |
| Mar | -3.21% | 11 |
| Apr | +2.12% | 11 |
| May | -5.33% | 11 |
| Jun | +5.30% | 11 |
| Jul | +0.71% | 11 |
| Aug | -0.54% | 10 |
| Sep | -0.19% | 10 |
| Oct | -2.51% | 10 |
| Nov | +8.93% | 10 |
| Dec | +0.54% | 11 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-01 | Pre-Market | 5.22% | 6.10% | 1.17x | Exceeded |
| 2024-11-06 | Pre-Market | 9.90% | 1.67% | 0.17x | Within |
| 2025-02-19 | Pre-Market | 9.03% | 0.57% | 0.06x | Within |
| 2025-04-30 | Pre-Market | 10.43% | 3.91% | 0.37x | Within |
| 2025-07-30 | Pre-Market | 12.30% | 4.56% | 0.37x | Within |
| 2025-10-29 | Pre-Market | 11.32% | 2.30% | 0.20x | Within |
| 2026-02-25 | Pre-Market | 11.14% | 4.81% | 0.43x | Within |
| 2026-04-29 | Pre-Market | 7.31% | 4.25% | 0.58x | Within |
| 2026-07-29 | Pre-Market | 10.04% | 2.28% | 0.23x | Within |
- IV Rank (30D)
- 64.26
- IV Rank (7D)
- 64.26
- Avg IV
- 88.7%
- Straddle (30D)
- $4.83
- Straddle (7D)
- $4.83
- P/C Volume
- 10.96
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
- Beta (1Y vs SPY)
- 0.15
- Correlation (SPY)
- 3.5%
- R²
- 0.00
- Ann. Volatility
- 52.8%
- SPY Volatility
- 12.9%
Low volatility - stock moves less than market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $56.75M | 39.70% | 2026-03-31 |
| 2 | JANE STREET GROUP, LLC Custodian | $21.68M | 15.16% | 2026-03-31 |
| 3 | JPMORGAN CHASE & CO Custodian | $11.97M | 8.37% | 2026-03-31 |
| 4 | CITADEL ADVISORS LLC Custodian | $8.66M | 6.06% | 2026-03-31 |
| 5 | Ikarian Capital, LLC | $8.42M | 5.89% | 2026-03-31 |
| 6 | CITIGROUP INC Custodian | $7.39M | 5.17% | 2026-03-31 |
| 7 | NOMURA HOLDINGS INC | $4.46M | 3.12% | 2026-03-31 |
| 8 | SIG BROKERAGE, LP | $4.13M | 2.89% | 2026-03-31 |
| 9 | IMC-Chicago, LLC Custodian | $3.81M | 2.67% | 2026-03-31 |
| 10 | BOOTHBAY FUND MANAGEMENT, LLC | $2.37M | 1.66% | 2026-03-31 |
| 11 | GROUP ONE TRADING LLC Custodian | $2.25M | 1.57% | 2026-03-31 |
| 12 | SIMPLEX TRADING, LLC Custodian | $1.67M | 1.17% | 2026-03-31 |
| 13 | TUDOR INVESTMENT CORP ET AL | $1.56M | 1.09% | 2026-03-31 |
| 14 | WOLVERINE TRADING, LLC Custodian | $1.55M | 1.09% | 2025-09-30 |
| 15 | Point72 Asset Management, L.P. | $1.50M | 1.05% | 2026-03-31 |
| 16 | J. Goldman & Co LP | $1.50M | 1.05% | 2026-03-31 |
| 17 | Walleye Capital LLC | $1.31M | 0.91% | 2026-03-31 |
| 18 | VELA Investment Management, LLC | $938.62K | 0.66% | 2026-03-31 |
| 19 | WOLVERINE ASSET MANAGEMENT LLC | $750.90K | 0.53% | 2026-03-31 |
| 20 | Raiffeisen Bank International AG | $131.71K | 0.09% | 2026-03-31 |
| 21 | TOCQUEVILLE ASSET MANAGEMENT L.P. | $75.09K | 0.05% | 2026-03-31 |
| 22 | PEAK6 LLC | $75.09K | 0.05% | 2026-03-31 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $34.11M | 23.53% | 2026-03-31 |
| 2 | SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | $33.79M | 23.31% | 2026-03-31 |
| 3 | JANE STREET GROUP, LLC Custodian | $21.01M | 14.49% | 2026-03-31 |
| 4 | CITADEL ADVISORS LLC Custodian | $18.64M | 12.86% | 2026-03-31 |
| 5 | JPMORGAN CHASE & CO Custodian | $11.97M | 8.25% | 2026-03-31 |
| 6 | SIMPLEX TRADING, LLC Custodian | $4.80M | 3.31% | 2026-03-31 |
| 7 | LMR Partners LLP | $3.86M | 2.66% | 2026-03-31 |
| 8 | BARCLAYS PLC Custodian | $3.75M | 2.59% | 2026-03-31 |
| 9 | WOLVERINE ASSET MANAGEMENT LLC | $2.63M | 1.81% | 2026-03-31 |
| 10 | SIG BROKERAGE, LP | $2.25M | 1.55% | 2026-03-31 |
| 11 | IMC-Chicago, LLC Custodian | $2.06M | 1.42% | 2026-03-31 |
| 12 | PEAK6 LLC | $1.52M | 1.05% | 2026-03-31 |
| 13 | CITIGROUP INC Custodian | $1.35M | 0.93% | 2026-03-31 |
| 14 | Point72 Asset Management, L.P. | $1.28M | 0.89% | 2026-03-31 |
| 15 | GROUP ONE TRADING LLC Custodian | $991.19K | 0.68% | 2026-03-31 |
| 16 | WOLVERINE TRADING, LLC Custodian | $686.40K | 0.47% | 2025-09-30 |
| 17 | CSS LLC/IL | $150.18K | 0.10% | 2026-03-31 |
| 18 | Walleye Capital LLC | $112.64K | 0.08% | 2026-03-31 |
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-17 | LUDWIG HANTSON | Director | Grant (A) | +3,399 RSU | — | EDGAR | |
| 2026-07-17 | Peter N Reikes | Director | Grant (A) | +3,399 RSU | — | EDGAR | |
| 2026-07-17 | JOAN E HERMAN | Director | Exer (M) | +5,220 | — | EDGAR | |
| 2026-07-17 | SPENCER R BERTHELSEN | Director | Exer (M) | +5,220 | — | EDGAR | |
| 2026-07-09 | Holly B. Kordasiewicz | EVP, Chief Development Officer | Sell (S) | −362 | $84.30 | -$30.5K | EDGAR |
| 2026-07-09 | Allene M. Diaz | Director | Mixed | — | $66.26 | -$387.3K | EDGAR |
| 2026-07-09 | C FRANK BENNETT | EVP, Chief Scientific Officer | Mixed | −5,536 | $84.95 | -$1.74M | EDGAR |
| 2026-07-06 | SPENCER R BERTHELSEN | Director | Grant (A) | +7,670 opt | — | EDGAR | |
| 2026-07-06 | JOAN E HERMAN | Director | Grant (A) | +7,670 RSU | — | EDGAR | |
| 2026-07-06 | Michael R Hayden | Director | Grant (A) | +7,670 opt | — | EDGAR | |
| 2026-07-06 | JOSEPH LOSCALZO | Director | Grant (A) | +7,670 opt | — | EDGAR | |
| 2026-07-06 | MICHAEL J. YANG | Director | Grant (A) | +7,670 RSU | — | EDGAR | |
| 2026-07-06 | JOSEPH III KLEIN | Director | Mixed | — | $59.49 | -$450.4K | EDGAR |
| 2026-07-06 | Allene M. Diaz | Director | Grant (A) | +7,670 RSU | — | EDGAR | |
| 2026-06-26 | Brett P Monia | Chief Executive Officer | Mixed | — | $63.21 | -$2.82M | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | STANLEY T CROOKE | Exec Chairman of the Board | 496,412 | $26.46M | -$50.31M | 51 | 2021-01-28 |
| 2 | ELIZABETH L HOUGEN | EVP, Finance & CFO | 254,221 | $13.55M | -$27.72M | 58 | 2026-03-18 |
| 3 | Brett P Monia | Chief Executive Officer | 245,571 | $13.09M | -$62.52M | 75 | 2026-06-26 |
| 4 | SPENCER R BERTHELSEN | Director | 161,303 | $8.60M | -$4.88M | 28 | 2026-07-17 |
| 5 | Richard S Geary | EVP, Chief Development Officer | 77,957 | $4.16M | -$23.74M | 60 | 2025-11-07 |
| 6 | C FRANK BENNETT | EVP, Chief Scientific Officer | 75,018 | $4.00M | -$31.71M | 71 | 2026-07-09 |
| 7 | Brian Birchler | EVP, Corp and Development Ops | 68,473 | $3.65M | -$4.04M | 20 | 2026-04-17 |
| 8 | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 63,890 | $3.41M | -$5.94M | 26 | 2026-03-23 |
| 9 | PATRICK R. O'NEIL | EVP CLO & General Counsel | 62,211 | $3.32M | -$30.73M | 83 | 2026-03-11 |
| 10 | FREDERICK T MUTO | Director | 58,432 | $3.12M | -$3.65M | 16 | 2022-07-19 |
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-07-07 | Diaz Allene M. | Director | 10,111 | $863.6K | 2026-07-07 | Stifel Nicolaus & Company Inc | 10b5-1 | EDGAR |
| 2026-07-07 | Kordasiewicz Holly B. | Officer | 1,287 | $108.5K | 2026-07-07 | Stifel Nicolaus & Company Inc | 10b5-1 | EDGAR |
| 2026-07-07 | BENNETT C FRANK | Officer | 67,386 | $5.72M | 2026-07-07 | Stifel Nicolaus & Company Inc | 10b5-1 | EDGAR |
| 2026-07-01 | KLEIN JOSEPH III | Director | 11,518 | $910.4K | 2026-07-01 | Stifel Nicolaus & Company Inc | 10b5-1 | EDGAR |
| 2026-06-26 | Baroldi Mariana | Member of immediate family of any of the foregoing | 5,635 | $451.7K | 2026-06-26 | Stifel Nicolaus & Company Inc | 10b5-1 | EDGAR |
| 2026-06-26 | O'NEIL PATRICK R. | Officer | 3,069 | $245.5K | 2026-06-26 | Stifel Nicolaus & Company Inc | 10b5-1 | EDGAR |
| 2026-06-26 | Schneider Eugene | Officer | 47,884 | $3.88M | 2026-06-26 | Stifel Nicolaus & Company Inc | 10b5-1 | EDGAR |
| 2026-06-25 | Swayze Eric | Officer | 10,602 | $839.3K | 2026-06-25 | Stifel Nicolaus & Company Inc | 10b5-1 | EDGAR |
| 2026-06-15 | BERTHELSEN SPENCER R | Director | 8,000 | $587.9K | 2026-06-15 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-06-12 | Kordasiewicz Holly B. | Officer | 60,846 | $4.47M | 2026-06-12 | Stifel Nicolaus & Company Inc | 10b5-1 | EDGAR |
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-28 | 0001140361-26-023093 | EDGAR |
| 2026-04-29 | 0001140361-26-017637 | EDGAR |
| 2026-04-21 | 0001140361-26-015801 | EDGAR |
| 2026-03-09 | 0001140361-26-008340 | EDGAR |
| 2026-02-25 | 0001140361-26-006718 | EDGAR |
| 2026-01-12 | 0001140361-26-000893 | EDGAR |
| 2026-01-07 | 0001140361-26-000435 | EDGAR |
| 2025-11-17 | 0001193125-25-284609 | EDGAR |
| 2025-11-10 | 0001140361-25-041225 | EDGAR |
| 2025-10-29 | 0001140361-25-039650 | EDGAR |
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-29 | 0000874015-26-000177 | EDGAR |
| 2025-10-29 | 0000874015-25-000266 | EDGAR |
| 2025-07-30 | 0000874015-25-000167 | EDGAR |
| 2025-04-30 | 0000874015-25-000123 | EDGAR |
| 2024-11-06 | 0000874015-24-000232 | EDGAR |
| 2024-08-01 | 0000874015-24-000187 | EDGAR |
| 2024-05-07 | 0000874015-24-000142 | EDGAR |
| 2023-11-02 | 0000874015-23-000209 | EDGAR |
| 2023-08-09 | 0000874015-23-000186 | EDGAR |
| 2023-05-03 | 0000874015-23-000136 | EDGAR |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 18.6 |
| P/S Ratio | 8.6 |
| EV/EBITDA | -31.4 |
| TTM Revenue | $1.1B |
| TTM Net Income | $-0.3B |
| TTM EPS | $-2.09 |
| ROE | -66.5% |
| Debt/Equity | 3.57 |